Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 4 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Garju Pharma from Waregem, company number BE0782512361, closed financial year 2025 with a result of € 61,923 after tax. For that financial year Garju Pharma recorded a gross margin of € 110,774 and equity of € 376,294. Compared with financial year 2024, the result moved from € 93,399 to € 61,923. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.
€ 376,294
▲ 20% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 61,923
▼ 34% vs 2024
Profit after tax over the fiscal year.
€ 11,880
▼ 40% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 226,294.
Debts at end 2025
€ 913,607
▼ 12% vs 2024
€ 121,651 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.
€ 16,940
▲ 120% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 29,936
▲ 16% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 68,261 | € 127,439 | € 159,077 | € 110,774 | ▼ 30% |
| Profit after taxes | € -5,735 | € 76,707 | € 93,399 | € 61,923 | ▼ 34% |
| Equity | € 144,265 | € 220,972 | € 314,371 | € 376,294 | ▲ 20% |
| Total debts | € 1,545,658 | € 1,400,269 | € 1,381,210 | € 1,304,744 | ▼ 6% |
| Cash | € 20,043 | € 8,545 | € 19,822 | € 11,880 | ▼ 40% |
| Land & buildings | € 385,845 | € 373,995 | € 437,057 | € 423,207 | ▼ 3% |
| Retained profit | € -5,735 | € 70,972 | € 164,371 | € 226,294 | ▲ 38% |
| Bank debt | € 1,271,771 | € 1,153,503 | € 1,034,119 | € 913,607 | ▼ 12% |
| Balance sheet total | € 1,689,923 | € 1,621,241 | € 1,695,580 | € 1,681,038 | ▼ 1% |
By gross margin, Garju Pharma ranks 9th of 26 companies with main activity “Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies” in Waregem that publish figures (fiscal year 2025).
Key figures of Garju Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about Garju Pharma the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Garju Pharma?
What happened at Garju Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 61,923 (▼ 34% vs 2024). Source: NBB ↗
- New establishment in Waregem. KBO
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- Stéphanie Goeminne became a director. NBB
- Anne-Sophie Mullie became a director. NBB
In short
From € 5,735 loss in 2022 to € 61,923 profit in 2025.
Paid € 57,963 in corporate taxes since 2022.
Best year ever: 2024, with € 93,399 profit.
Management
Behind Garju Pharma are Stéphanie Goeminne and Anne-Sophie Mullie. It owns 100% of Vijve apotheek itself.
Directors
According to the 2025 annual accounts
since 2022
Anne-Sophie Mullie
Bedrijfsrevisor en revisor erkend voor financiële instellingen
since 2022
Establishments
Establishment units
Physical locations of this company
Aloise Biebuyckstraat 13
8793 Waregem
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Waregem
Same main activity (Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies), 34 active companies in Waregem, largest first.
DEWAELE MANAGEMENT & INVESTMENT
€ 1.5 million revenue · 2025
€ 615,981 gross margin · 2025
€ 355,101 gross margin · 2025
€ 256,301 gross margin · 2025
€ 166,236 gross margin · 2025
€ 138,771 gross margin · 2025
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- Goeminne Stéphanie Monique(oprichter) 66.7%
- Mullie Anne-Sophie Marie(oprichter) 33.3%
Details
- Company number
- 0782.512.361
- VAT number
- BE 0782.512.361
- Registered office
- Aloise Biebuyckstraat 13, 8793 Waregem
- Names & denominations
- Garju Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 23 February 2022
- Peppol
- Active · Active since 24 Nov 2023
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Activiteiten van holdings
Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Adviesbureaus op het gebied van public relations en communicatie
Holdings